Kornimate/medical-research-clean huggingface dataset:
preservation of spontaneous breathing in patients undergoing thoracoscopic surgery

Conditions: Thoracoscopic Surgery

Summary: the aim of this study is to evaluate the advantages of the non-intubation compared with intubation anesthesia on enhanced recovery after thoracoscopic surgery

all patients will be screened to determine eligibility for study entry, and the patients who meet the eligibility requirements will be informed about the study and potential risks. after giving written informed consent, the patients were randomly divided into non-intubation group and intubation group

Eligibility criteria:
inclusion criteria: * age 18-69 years old * body mass index (bmi) was 18-24 kg / m2 * american society of anesthesiologists' physical classification class i-ii * the preoperative pulmonary function was normal exclusion criteria: * severe cardiopulmonary disease * severe nervous system diseases * severe blood system diseases * severe liver and kidney dysfunction * conversion to thoracotomy

Keywords: spontaneous breathing anesthesia
tace in combination with pd-1/pd-l1 inhibitors and molecular target therapies for intermediate hcc

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (tace) in combination with pd-1/pd-l1 inhibitors and molecular target therapies in patients with intermediate-stage hepatocellular carcinoma (hcc).

transarterial chemoembolization (tace) can induce immunogenic cell death and tumor-specific immune response which results in the release of tumor antigens and transform "cold" tumors with lacking immune effector cells into "hot" tumors with immune effector cells infiltration. this provides a theoretical basis for tace combined with immune checkpoint inhibitors (icis) in hepatocellular carcinoma (hcc) patients. the purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (tace) in combination with pd-1/pd-l1 inhibitors and molecular target therapies(including, vegf-tki/ bevacizumab) in patients with intermediate-stage hcc. this real-world study also would like to explore the optimal combined treatment and subgroup of hcc patients for providing further information for clinical practice and trials.

Eligibility criteria:
inclusion criteria: 1. has a diagnosis of hcc confirmed by radiology, histology, or cytology; 2. barcelona clinic liver cancer (bclc) stage b, without the presence of extrahepatic spread and/or macrovascular invasion; 3. has not received any previous tace/haic and systemic therapy for hcc (including chemotherapy, molecularly targeted therapy, immunotherapy); 4. both pd-1/pd-l1 inhibitors and anti-angiogenesis drugs patients received only include marketed drugs but are not limited to hcc approval; 5. tace was performed after the first pd-1/pd-l1 inhibitor/anti-angiogenic drug treatment or before treatment; 6. received at least 1 cycle of pd-1/pd-l1 inhibitor/anti-angiogenic drug combination therapy after tace treatment； 7. has repeated measurable intrahepatic lesions according to mrecist; exclusion criteria: 1. cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, and mixed hepatocellular/cholangiocarcinoma subtypes(confirmed by histology, or pathology) are not eligible; 2. unable to meet criteria of combination timeframe described above;

Keywords: hepatocellular carcinoma transarterial chemoembolization immune checkpoint inhibitors molecular target therapies intermediate stage
observational study for lung cancer patients treated with nivolumab

Conditions: Lung Cancer

Summary: this study will describe the characteristics of patients initiating nivolumab treatment for lung cancer and their outcomes over 3 years in france


Eligibility criteria:
inclusion criteria: * male or female: 18 age at the time of nivolumab initiation * pathologically confirmed diagnosis of lung cancer * patient initiating nivolumab :therapeutic decision to initiate nivolumab must be taken by the physician prior to enrolling a patient in the study exclusion criteria: -patient taking part in an interventional study for lung cancer treatment for which nivolumab is 1 of the investigational drugs other protocol defined inclusion or exclusion criteria could apply
tele-monitoring of post join arthroplasty outcomes: a feasibility study

Conditions: Post-Op Complication

Summary: the purpose of this study is to develop an effective telephone mediated follow-up system to reduce the number of unplanned readmissions and emergency department visits after total joint arthroplasty. this will help reduce costs related to unnecessary visits to the hospital as well as catch complications earlier on. the investigators plan to accomplish this by performing a pilot study that will compare the outcomes of using an interactive voice response system through phone call in addition to the standard follow-up protocol. the outcomes of this group will be compared to those receiving the standard of care follow-up protocol.

upon patient education and consent to participate in this study, patients will be randomized via online randomizer during their baseline visit into either treatment as usual (tau) or integrated voice response (ivr) cohorts. during this baseline visit, the patients in the ivr group will be given specific information on the nature of the calls and what to expect. both groups will fill out a form for assessing their baseline pain and functionality. both groups will receive standard total joint arthroplasty. after this, the tau group will receive the standard of care which involves appropriate pain management and scheduled clinic follow-ups lasting approximately 60 minutes at 2 weeks, 6 weeks, and 12 weeks along with additional visits if required. clinic visits will assess pain via vas scale, joint functionality via hoos and koos scale, and quality of life via sf-36. in addition to the standard of care follow-up visits as in the tau group, the ivr group will also receive automated phone calls lasting up to 3 minutes, which will be the focus of this research study. these phone calls will be daily for the first week, every other day the second week, twice a week for weeks 3-6, and weekly for weeks 7-12. the content of these calls will assess pain management, wound healing and screen for potential complications through a series of questions (questionnaire script attached). at the completion of each call, the patient will be instructed to either continue standard treatment or visit the emergency department based on the content of their response. if there is reason for concern, the pi will automatically be informed. survey questions pertaining to the patients outcomes and satisfaction will be completed in clinic and collected by the pi. the responses and data relating to ivr calls will made available through computer software designed by our team on the secure redcap network.

Eligibility criteria:
inclusion criteria: * participants eligible to undergo the tja surgical procedure exclusion criteria: * participants who are not eligible to undergo the tja surgical procedure

Keywords: telemedicine knee replacement hip replacement
madrid - tolerance and acceptability study

Conditions: Dysphagia

Summary: tolerance and acceptability of a gum based thickener.

to evaluate the tolerance and acceptability of aymes madrid, in patients that may require modified consistency fluids. measuring gi tolerance, compliance, convenience and preference. to obtain data to support an acbs submissions for aymes madrid (to allow for prescription in the community at nhs expense).

Eligibility criteria:
inclusion criteria: * adult patients (≥18 years) who are able to communicate clearly. * patients with dysphagia requiring stage 1, 2 or 3 thickened fluids as determined by -speech and language therapist. * patients expected to require provision of stage 1, 2 or 3 thickened fluids for at least 2 further weeks. * informed consent obtained from patient or for those without capacity following consultation with carers. exclusion criteria: * patients with maize / corn allergy requiring a maize free diet * patients with inherited metabolic conditions. * patients requiring enteral tube feeding or parenteral nutrition. * patients with medical or dietary contraindication to any feed ingredients * patients with delayed oral phase of swallowing. * patients with significant renal (requiring dialysis) or hepatic impairment (e.g. hepatitis) * patients with dysphagia not requiring stage 1, 2 or 3 thickened fluids. * patients with uncontrolled inflammatory bowel disease or previous bowel resection with ongoing gastrointestinal symptoms. * patients for whom the investigator has concerns regarding the ability or willingness of the patient and or carer to comply with protocol requirements * participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study (to prevent over burdening of participants and ensure a period of normalisation between study involvement)
1.2% rosuvastatin gel as a local agent in smokers with chronic periodontitis

Conditions: Chronic Periodontitis

Summary: the purpose of the present study was to evaluate the effects of subgingival delivery of rosuvastatin gel as an adjunct to scaling and root planing in smokers with chronic periodontitis (cp) patients.

background: periodontal diseases are multi-factorial in etiology, and bacteria are one among these etiologic agents. however, mechanical therapy itself may not always reduce or eliminate the anaerobic infection at the base of the pocket, within the gingival tissues. to overcome this, various systemic and local drug delivered antimicrobials have been used as an adjunct to scaling and root planing (srp).the present study aims to explore the efficacy of 1.2% rosuvastatin (rsv) gel local drug delivery as an adjunct to srp in smokers with chronic periodontitis (cp). methods: sixty subjects were randomly allocated into two treatment groups: srp with placebo gel (group 1), srp with 1.2% rsv gel (group 2). clinical parameters were recorded at baseline, 6 and 9 months. radiographic assessment was done using computer aided software at baseline, 6 and 9 months.

Eligibility criteria:
inclusion criteria: * systemically healthy cp subjects aged between 30-50 years who are current smokers with no history of periodontal therapy or use of antibiotics in past 6 months, having sites with intrabony defect depth (ibd) ≥ 3mm (distance between alveolar crest and base of the defect on intraoral periapical radiograph) along with ppd ≥5 mm or cal ≥3 mm in an asymptomatic tooth were included in the study. a subject was considered as a current smoker if he regularly smoked more than 10 cigarettes/day for a minimum of 5 years exclusion criteria: * former smokers, i.e. subjects who had previously been smokers but stopped their habit, and non-smokers were excluded. subjects allergic to statins, on systemic statin therapy, with any known systemic disease or any other systemic inflammation/ infection which could alter the course of periodontal disease and users of tobacco in any other form than cigarettes were excluded from the study
peritoneal nebulization of ropivacaine for pain control after laparoscopic colectomy

Conditions: Postoperative Pain

Summary: the purpose of this study is to assess if intraperitoneal nebulization of ropivacaine 150 mg produces better postoperative pain control than saline nebulization after laparoscopic colectomy.

recently intraperitoneal nebulization of local anesthetic has been used as an alternative to direct intraperitoneal instillation. intraperitoneal aerosolization of bupivacaine 50 mg after laparoscopic cholecystectomy significantly reduced postoperative pain, morphine consumption and incidence of postoperative nausea and vomiting and it is associated with rapid mobilization compared with patients receiving direct instillation of bupivacaine 50 mg or placebo. in a recent study the investigators found that nebulization of ropivacaine 30 mg with the aeronebpro® before or after laparoscopic cholecystectomy and gynecologic laparoscopic surgery reduces postoperative pain and morphine consumption. patients receiving preoperative nebulization of ropivacaine presented significantly less postoperative pain (-50% clinical setting) and consumed significant less morphine (-50% and -40% respectively) than patients in control groups during the first 48 hours after surgery. the effects of peritoneal nebulization of ropivacaine during laparoscopic colectomy on pain control and morphine consumption were not evaluated. the investigators hypothesize that intraperitoneal nebulization of ropivacaine may produce better pain control and less morphine consumption than nebulization of saline after laparoscopic colectomy.

Eligibility criteria:
inclusion criteria: * females and males 18-80 years old * asa score i (american society of anesthesiologists classification : a normal healthy patient. * asa score ii (american society of anesthesiologists classification): a patient with mild systemic disease * asa score iii (american society of anesthesiologists classification): a patient with severe systemic disease * patients scheduled for oncological laparoscopic colectomy * patients who do not use opioids analgesic drugs before surgery * patients without cognitive impairment or mental retardation exclusion criteria: * females and males under 18 or over 80 * asa score iv (american society of anesthesiologists classification): a patient with severe systemic disease that is a constant threat to life * asa score v (american society of anesthesiologists classification): a moribund patient who is not expected to survive without the operation * emergency/urgency surgery * postoperative admission in an intensive care unit with sedation or ventilatory assistance * cognitive impairment or mental retardation * use of opiods before surgery * progressive degenerative diseases of the cns * convulsions or chronic therapy with antiepileptic drugs * severe hepatic or renal impairment * allergy to one of the specific drugs under study * acute infection or inflammatory chronic disease * alcohol or drug addiction * any kind of communication problem * neurologic or psychiatric disease

Keywords: laparoscopic colectomy nebulization ropivacaine
cv risk factors at age 25-64 & long-term medicare costs

Conditions: Cardiovascular Diseases; Heart Diseases

Summary: to assess in four large chicago population cohorts whether young adult and middle-aged risk factor status has an impact not only on average annual medicare costs, but also on cumulative and lifetime medicare costs, to ages 70, 75, 80, \>80, including to death, and during the last one to two years of life.

background: studies will be conducted on the cumulative lifetime medicare costs of individuals from four chicago population cohorts from which prior risk factor data are available. one cohort is from the western electric company study, with 2107 men who were 40-56 when the follow up began in 1957. for this group a physical exam, ecg and cholesterol measures are available along with data from a quantitative diet history conducted at that time assessing 28 days of intake. it is not clear whether the men themselves or their wives provided this information. repeat measures are available, but attention is paid to their use in the analyses. also, information on the availability of the quantitative information at the food level is not provided. two cohorts are from the peoples gas company study, one with 1594 men aged 40-59 in 1958 and the second with 1609 men aged 25-39 in 1959 . from both cohorts a total of 1802 men are, based on their ages, currently medicare eligible.the fourth cohort is the chicago heart disease detection association project (cha) based on an initial survey of 39,573 men and women conducted in 1967-1973 on whom dietary data are not available. design narrative: the study assesses the relationships of cvd risk factors measured in young and middle-aged adult men and women to medicare utilization and charges, from medicare enrollment to death or attainment of age 70, 75, 80, \>80, including in the last one to two years of life. the study determines long-term relationship between earlier low-risk status vs. not-low-risk to subsequent medicare health care charges. baseline low risk is all six cvd risk factors favorable: systolic/diastolic pressure 120 mmhg/80 mmhg and no antihypertensive treatment, serum cholesterol \<200 mg/dl, not currently smoking, no ecg abnormalities, no history of diabetes or heart attack. the study also determines the relationships between baseline habitual eating patterns and subsequent medicare utilization and charges. further statistical methods are developed for optimal analyses of health care expenditures. the database will be extended by obtaining additional years of morbidity-mortality experience and of medicare charge data to the year 2002.

Eligibility criteria:
testing and development of a sleep training mobile health application

Conditions: Sleep

Summary: the specific aims of this study are : 1) to pilot test the alpha build prototype of the sleep training smartphone application using a sample of parents looking for sleep training advice online. 1a) to assess the efficacy of the application in helping parents with the sleep training process 1b) to assess the 'workability' of the application 2) use feedback to guide the next round of development with the goal of building out the applications functionality and increasing usability.

problems with bedtime and night-wakings are common in early childhood. behavioral interventions to address these sleep problems are commonly referred to as "sleep training" and are effective but difficult for some parents to perform. the investigators have developed a prototype of a novel smartphone application designed to assist parents throughout this process. the smartphone application first collects basic information from the parents, including: first name of child, number of caregivers participating in bedtime, tolerance of caregivers for crying, and basic information about timing of sleep and wake, as well as information about the usual order of events at bedtime. at each step, a brief (2-3 paragraph) is provided to explain the rationale for the next step, as well as concrete advice on how to succeed. it then walks parents through proven techniques to improve sleep in children in a stepwise fashion.

Eligibility criteria:
inclusion criteria: * english speaking * parent of child age 6-24 months * target child sleeping in crib in his or her own room (not the same room as the parents or a sibling) * actively looking to sleep train their child * own an ios or android smartphone exclusion criteria: * bedsharing/cosleeping with child * target child has a known developmental delay * target child has a significant health issue affecting his/her sleep (failure to thrive, congenital heart disease, etc).
effect on ocular surface symptoms of online education

Conditions: Eye Diseases; Ocular Surface Disease; Dry Eye

Summary: retrospective, observational study.

aim: the aim of this study was to investigate the effects on ocular surface symptoms of students taking online education, which was a part of the distance learning model during the covid-19 pandemic, to be able to prevent the formation of irreversible damage with early diagnosis and treatment. with recommendations that can be simply applied, it was aimed to protect ocular health. material and method: the study included 315 students who were undertaking online education and presented at the ophthalmology department of a tertiary level university hospital. a record was made of sociodemographic data, schirmer test results, tear break-up time (tbut) measurements, and ocular surface disease index (osdi) scores. the data were analyzed statistically using spss vn. 22.0 software, and a value of p\<0.05 was accepted as statistically significant.

Eligibility criteria:
inclusion criteria: online education \>6 years \<30 years student exclusion criteria: not student not taking online education \ 30 years

Keywords: pandemic online education ocular health tear break up time schirmer
multicenter study of nontuberculous mycobacteria in cystic fibrosis patients

Conditions: Cystic Fibrosis; Atypical Mycobacterium Infection

Summary: objectives: i. determine the prevalence of nontuberculous mycobacteria in sputum cultures from patients with cystic fibrosis. ii. compare the clinical course of patients with negative versus positive cultures.

protocol outline: participants are screened for nontuberculous mycobacteria (ntm) with 3 sputum acid-fast bacilli smears and mycobacterial cultures, with speciation of positive cultures, collected over 1 year. demographic data, diagnostic criteria, clinical measurements, and other respiratory pathogen data are collected using the cystic fibrosis foundation patient registry questionnaire. ntm-positive patients (cases) matched with ntm-negative controls identified in screening are followed every 3 months for 15 months. cases are evaluated for ntm burden during the first 3 months. appropriate therapy is offered to consistently ntm-positive cases. lung transplant recipients are removed from study.

Eligibility criteria:
protocol entry criteria: patients over age 10 with cystic fibrosis documented as follows: * pilocarpine sweat chloride test at least 60 meq/l or * genotyping or transepithelial potential difference and * clinical symptoms of suppurative respiratory disease or pancreatic insufficiency able to produce at least 3 sputum samples * bronchoscopy specimens acceptable * throat/nasal specimens not acceptable no pseudomonas cepacia colonization

Keywords: atypical mycobacterium infection bacterial infection cardiovascular and respiratory diseases cystic fibrosis genetic diseases and dysmorphic syndromes immunologic disorders and infectious disorders mycobacterium infection rare disease
study on osseospeed™ tx short implants in a chinese population

Conditions: Partially Edentulous Jaw

Summary: the purpose of this study is to investigate the clinical efficacy of osseospeed™ tx 6 mm implants in a chinese population by evaluation of marginal bone level alteration, implant stability and implant survival in the posterior mandible and maxilla up to 3 years after loading. the hypothesis is that one stage surgery using 6 mm osseospeed™ tx implant in the posterior region is safe and predictable.


Eligibility criteria:
inclusion criteria: 1. provision of informed consent 2. female and male aged 20-75 years at enrolment 3. in need for 2-3 implants in either side of the posterior mandible or maxilla (premolar and molar region) 4. history of edentulism in the study area of at least four months 5. neighboring tooth/teeth to the planned bridge/crowns must have natural root(s) 6. presence of natural teeth, partial prosthesis and/or implants in the opposite jaw in contact with the planned bridge/crowns 7. deemed by the investigator to be suitable for implants of 6 mm length and to have a bone height of at least 6 mm and a bone width of minimum 6 mm 8. deemed by the investigator as likely to present an initially stable implant situation exclusion criteria: 1. unlikely to be able to comply with study procedures, as judged by the investigator 2. earlier graft procedures in the study area 3. uncontrolled pathologic processes in the oral cavity 4. known or suspected current malignancy 5. history of radiation therapy in the head and neck region 6. history of chemotherapy within 5 years prior to surgery 7. systemic or local disease or condition that could compromise post-operative healing and/or osseointegration 8. uncontrolled diabetes mellitus 9. corticosteroids or any other medication that could influence post-operative healing and/or osseointegration 10. smoking more than 10 cigarettes/day 11. present alcohol and/or drug abuse 12. involvement in the planning and conduct of the study (applies to both astra tech staff and staff at the study site) 13. previous enrolment in the present study 14. simultaneous participation in another clinical study, or participation in a clinical study during the last 6 months 15. subjects that are unable to give informed consent